- Home
- MRSN vs SGMO Comparison
MRSN vs SGMO Comparison
Compare MRSN & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRSN | SGMO |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.8M | 155.1M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MRSN | SGMO |
|---|---|---|
| Price | $29.08 | $0.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $30.38 | $4.71 |
| AVG Volume (30 Days) | 52.9K | ★ 5.7M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,180,000.00 | $32,875,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.21 | $0.38 |
| 52 Week High | $40.88 | $2.73 |
Technical Indicators
Market Signals| Indicator | MRSN | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 82.82 | 40.60 |
| Support Level | $28.85 | $0.43 |
| Resistance Level | $29.39 | $0.49 |
| Average True Range (ATR) | 0.46 | 0.02 |
| MACD | -0.53 | -0.00 |
| Stochastic Oscillator | 77.67 | 3.99 |
Price Performance
Historical ComparisonAbout MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.